Poly Medicure Quarterly Results for Trading Insights
In Mar 2026, Poly Medicure (POLYMED) reported revenue ₹554 Cr and net profit ₹65 Cr — revenue +18.6% YoY. Also explore POLYMED share price history to track price trends across different timeframes.
POLYMED Quarterly Results — Revenue, Profit & EPS Highlights
Poly Medicure latest quarter revenue, net profit, EPS and QoQ/YoY growth rates. For annual financials, live price and key ratios, visit Poly Medicure screener.
- Revenue of ₹554 Cr in Mar 2026 (-1.1% vs Jun 2026, +18.6% vs Mar 2025)
- Net Profit of ₹65 Cr in Mar 2026 (-23.5% vs Jun 2026, -29.3% vs Mar 2025)
- EBITDA of ₹130 Cr in Mar 2026 (-18.8% vs Jun 2026)
- Operating Margin of 21.0% in Mar 2026 (-3.0pp vs Jun 2026)
- Earnings Per Share of ₹6.54 in Mar 2026 (-23.0% vs Jun 2026)
Poly Medicure Quarterly Results — Revenue, EBITDA, Net Profit & EPS
POLYMED quarterly revenue, expenses, EBITDA, net profit, EPS and operating margin with QoQ and YoY comparison.
| Metric | Mar 2026 | Jun 2026 | Sept 2025 | Mar 2025 | Jun 2025 | QoQ | YoY |
|---|---|---|---|---|---|---|---|
| Revenue (₹ Cr) | 554 | 560 | 479 | 467 | 447 | -1.1% | 18.6% |
| Net Profit (₹ Cr) | 65 | 85 | 92 | 92 | 93 | - | - |
| EBITDA (₹ Cr) | 130 | 160 | 150 | 146 | 149 | - | - |
| EPS (₹) | 6.54 | 8.49 | 9.06 | 8.92 | 9.19 | - | - |
| Operating Margin (%) | 21.0% | 24.0% | 26.0% | 27.0% | 26.0% | - | - |
POLYMED Share Price Trend — 1-Year Movement Across Quarterly Results
Poly Medicure 1-year share price in ₹ overlaid with quarterly earnings dates — NSE/BSE closing prices. Browse Poly Medicure annual reports for revenue, profit, balance sheet and cash flow data.
Revenue Trend (₹ Cr)
Net Profit Trend (₹ Cr)
Operating Margin Trend (%)
POLYMED vs Healthcare Peers — Quarterly Revenue, Profit & Market Cap
Poly Medicure latest quarter revenue and net profit vs Healthcare competitors — market cap, price and earnings comparison.
| Company Latest Quarter | Market Cap (₹ Cr) | Price (₹) | Revenue (₹ Cr) | Net Profit (₹ Cr) | Rev QoQ % | Rev YoY % | Profit Margin % | P/E Ratio |
|---|---|---|---|---|---|---|---|---|
|
Sun Pharmaceutical
Mar 2026 |
₹463,071.60 Cr | 1875.1 | 15,018 | 2,710 | -5.6% | - | 18.0% | 165.9 |
|
Divis Laboratories
Mar 2026 |
₹225,157.18 Cr | 8588.0 | 2,986 | 751 | -5.0% | - | 25.2% | 303.4 |
|
Torrent Pharmaceuti…
Mar 2026 |
₹188,719.51 Cr | 4971.0 | 4,111 | 364 | +27.7% | +42.2% | 8.9% | 431.9 |
|
Cipla
Mar 2026 |
₹117,137.57 Cr | 1431.1 | 6,612 | 543 | -9.3% | - | 8.2% | 208.3 |
|
Zydus Life Science
Mar 2026 |
₹113,855.38 Cr | 1115.6 | 7,569 | 1,341 | -4.3% | - | 17.7% | 88.2 |
All amounts in ₹ Crores